Extracranial malignant rhabdoid tumor, eMRT
Conditions
Interventions
Standardized Risk Group:AVDC/ICE alternating treatment program
High risk group:AVDC/ICE alternating treatment program + Bevacizumab
Sponsors
Beijing Childrens Hospital,Capital Medical University
Eligibility
Sex/Gender
All
Age
No minimum to 18 Years
Inclusion criteria
Inclusion criteria: 1.Age of onset under 18 years; 2.Pathomorphologic diagnosis of eMRT consistent with immunohistochemistry INI1(-)/genetic testing results showing deletion or mutation of the SMARCB1 gene, or immunohistochemistry BRG1 negative/genetic testing for deletion or mutation of the SMARCA4 gene; 3.Lansky (16 years old) has a Strength Conditioning Score of at least 60, Karnofsky (16 years old) has a Strength Conditioning Score of at least 60; 4.Expected survival of not less than 12 weeks; 5.Tumors may involve the central nervous system but originate in the non-central nervous system; 6.The patient or/family member voluntarily participates in the trial and signs an informed consent form; 7.Primary cases;
Exclusion criteria
Exclusion criteria: 1.Inability or unwillingness of study participants or legal guardians to provide written informed consent; 2.Serious congenital diseases with potentially life-threatening conditions; 3.Other serious complications that the investigators believe prevented the child from undergoing chemotherapy or receiving anti-angiogenic medications;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall survival rate;Event-free survival; | — |
Countries
China
Contacts
Public ContactHuanmin Wang
Beijing Childrens Hospital,Capital Medical University
Outcome results
None listed